Ambuja Cements Limited (AMBUJACEM) — Financial Results | 3 August 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Ambuja Cements reported Q1 FY27 financial results and strategic updates in investor call
🔄 What Changed
EBITDA margin improved 331 bps YoY to 16.7%, net profit rose to INR660 crores, and cost savings of INR206 per ton were achieved through logistics and renewable energy initiatives
🔮 What's Next
Target net operating cost of INR4,250 per ton by FY27 end, capacity expansion to reach 119 million tons by FY27, and 8-10 million tons annual capacity additions planned for FY28-FY29
💡 Investor Takeaway
Focus on cost optimization and value-driven growth positions Ambuja Cements to improve profitability despite industry headwinds

Ambuja Cements reported Q1 FY27 revenue of INR9,500 crores and net profit of INR660 crores, with EBITDA at INR1,589 crores and margin expanding 331 basis points to 16.7%. Management highlighted cost leadership through INR206 per ton net reductions, driven by logistics, renewable energy, and clinker factor improvements, while targeting INR4,250 per ton net operating cost by FY27 end. Capacity expansion projects across six locations aim to reach 119 million tons by FY27 end, prioritizing value-driven growth over volume. Regional volume mix shows growth in West and North, with deliberate degrowth in low-margin South. Capex spending reached 25% of the INR6,500 crore target, and renewable energy capacity increased to 1,132 MW. Management maintained full-year cost guidance despite inflation, citing offsetting savings from fly ash, power sales, and logistics efficiencies.

📄 View Original Announcement (PDF)

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AMBUJACEM — Free

Free account · 2 AI queries/day